請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9246
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 莊雅惠 | |
dc.contributor.author | Tzu-Chun Wang | en |
dc.contributor.author | 王姿君 | zh_TW |
dc.date.accessioned | 2021-05-20T20:14:26Z | - |
dc.date.available | 2012-09-15 | |
dc.date.available | 2021-05-20T20:14:26Z | - |
dc.date.copyright | 2009-09-15 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-07-20 | |
dc.identifier.citation | 1. Lee, Y.-L., Y.-C. Lin, B.-F. Hwang, and Y. L. Guo. 2005. Changing prevalence of asthma in taiwanese adolescents: two surveys 6 years apart. Pediatric Allergy and Immunology 16:157-164.
2. Eder, W., M. J. Ege, and E. von Mutius. 2006. The asthma epidemic. The New England Journal of Medicine 355:2226-2235. 3. Meyer, E. H., R. H. DeKruyff, and D. T. Umetsu. 2008. T cells and NKT cells in the pathogenesis of asthma. Annual Review of Medicine 59:281-292. 4. Van Hove, C. L., T. Maes, G. F. Joos, and K. G. Tournoy. 2008. Chronic inflammation in asthma: a contest of persistence vs resolution. Allergy 63:1095-1109. 5. Serhan, C. N., S. D. Brain, C. D. Buckley, D. W. Gilroy, C. Haslett, L. A. J. O'Neill, M. Perretti, A. G. Rossi, and J. L. Wallace. 2007. Resolution of inflammation: state of the art, definitions and terms. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 21:325-332. 6. Serhan, C. N., and J. Savill. 2005. Resolution of inflammation: the beginning programs the end. Nature immunology 6:1191-1197. 7. Lawrence, T., and D. W. Gilroy. 2007. Chronic inflammation: a failure of resolution? International Journal of Experimental Pathology 88:85-94. 8. Bousquet, J., P. K. Jeffery, W. W. Busse, M. Johnson, and A. M. Vignola. 2000. Asthma . From bronchoconstriction to airways inflammation and remodeling. American Journal of Respiratory and Critical Care Medicine 161:1720-1745. 9. Busse, W. W., and R. F. Lemanske. 2001. Asthma. The New England Journal of Medicine 344:350-362. 10. Barnes, P. J. 2008. Immunology of asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology 8:183-192. 11. Takatsu, K., T. Kouro, Y. Nagai, and W. A. Frederick. 2009. Chapter 6 interleukin 5 in the link between the innate and acquired immune response. In Advances in Immunology. Academic Press. 191-236. 12. Dent, L., M. Strath, A. Mellor, and C. Sanderson. 1990. Eosinophilia in transgenic mice expressing interleukin 5. Journal of Experimental Medicine 172:1425-1431. 13. Foster, P., S. Hogan, A. Ramsay, K. Matthaei, and I. Young. 1996. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. Journal of Experimental Medicine 183:195-201. 14. Barnes, P. J., and J. M. Drazen. 2002. Asthma and COPD. Academic Press, San Diego, CA :. 15. Rothenberg, M. E. 1998. Eosinophilia. The New England Journal of Medicine 338:1592-1600. 16. Nickel, R., L. A. Beck, C. Stellato, and R. P. Schleimer. 1999. Chemokines and allergic disease. Journal of Allergy and Clinical Immunology 104:723-742. 17. Gleich, G. J. 1990. The eosinophil and bronchial asthma: current understanding. Journal of Allergy and Clinical Immunology 85:422-436. 18. Morishima, Y., Y. Ishii, T. Kimura, A. Shibuya, K. Shibuya, A. E. Hegab, T. Iizuka, T. Kiwamoto, Y. Matsuno, T. Sakamoto, A. Nomura, M. Taniguchi, and K. Sekizawa. 2005. Suppression of eosinophilic airway inflammation by treatment with α-galactosylceramide. European Journal of Immunology 35:2803-2814. 19. Traves, S. L., S. J. Smith, P. J. Barnes, and L. E. Donnelly. 2004. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. Journal of Leukocyte Biology 76:441-450. 20. Barnes, P. J. 2004. Alveolar Macrophages As Orchestrators of COPD. COPD: journal of chronic obstructive pulmonary disease 1:59 - 70. 21. Brusselle, G. G., J. C. Kips, J. H. Tavernier, J. G. Heyden, C. A. Cuvelier, R. A. Pauwels, and H. Bluethmann. 1994. Attenuation of allergic airway inflammation in IL-4 deficient mice. Clinical and Experimental Allergy 24:73-80. 22. de Vries, J. E. 1998. The role of IL-13 and its receptor in allergy and inflammatory responses. Journal of Allergy and Clinical Immunology 102:165-169. 23. Li, L., Y. Xia, A. Nguyen, Y. H. Lai, L. Feng, T. R. Mosmann, and D. Lo. 1999. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. Journal of Immunology 162:2477-2487. 24. Li, X., R. Chopra, T. Chou, B. Schofield, M. Wills-Karp, and S. Huang. 1996. Mucosal IFN-γ gene transfer inhibits pulmonary allergic responses in mice. Journal of Immunology 157:3216-3219. 25. Finotto, S., M. F. Neurath, J. N. Glickman, S. Qin, H. A. Lehr, F. H. Y. Green, K. Ackerman, K. Haley, P. R. Galle, S. J. Szabo, J. M. Drazen, G. T. De Sanctis, and L. H. Glimcher. 2002. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 295:336-338. 26. Takaoka, A., Y. Tanaka, T. Tsuji, T. Jinushi, A. Hoshino, Y. Asakura, Y. Mita, K. Watanabe, S. Nakaike, Y. Togashi, T. Koda, K. Matsushima, and T. Nishimura. 2001. A critical role for mouse CXC chemokine(s) in pulmonary neutrophilia during Th type 1-dependent airway inflammation. Journal of Immunology 167:2349-2353. 27. Gould, H. J., R. L. Beavil, and D. Vercelli. 2000. IgE isotype determination: epsilon-germline gene transcription, DNA recombination and B-cell differentiation. British Medical Bulletin Allergy and Allergic Diseases: with A View to the Future 56:908-924. 28. Hammad, H., and B. N. Lambrecht. 2006. Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. Journal of Allergy and Clinical Immunology 118:331-336. 29. Ying, S., B. O'Connor, J. Ratoff, Q. Meng, K. Mallett, D. Cousins, D. Robinson, G. Zhang, J. Zhao, T. H. Lee, and C. Corrigan. 2005. thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. Journal of Immunology 174:8183-8190. 30. Soumelis, V., P. A. Reche, H. Kanzler, W. Yuan, G. Edward, B. Homey, M. Gilliet, S. Ho, S. Antonenko, A. Lauerma, K. Smith, D. Gorman, S. Zurawski, J. Abrams, S. Menon, T. McClanahan, R. d. Waal-Malefyt, F. Bazan, R. A. Kastelein, and Y.-J. Liu. 2002. Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nature immunology 3:673-680. 31. Cohn, L., J. A. Elias, and G. L. Chupp. 2004. Asthma: mechanisms of disease persistence and progression. Annual Review of Immunology 22:789-815. 32. Martinez, F. D. 2003. Toward asthma prevention -- does all that really matters happen before we learn to read? The New England Journal of Medicine 349:1473-1475. 33. Sears, M. R., J. M. Greene, A. R. Willan, E. M. Wiecek, D. R. Taylor, E. M. Flannery, J. O. Cowan, G. P. Herbison, P. A. Silva, and R. Poulton. 2003. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. The New England Journal of Medicine 349:1414-1422. 34. Galli, S. J. 1997. Complexity and redundancy in the pathogenesis of asthma: reassessing the roles of mast cells and T cells. Journal of Experimental Medicine 186:343-347. 35. Rossi, G. L., and D. Olivieri. 1997. Does the mast cell still have a key role in asthma? Chest 112:523-529. 36. Wills-Karp, M. 1999. Immunologic basis of antigen-induced airway hyperresponsiveness. Annual Review of Immunology 17:255-281. 37. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annual Review of Immunology 25:297-336. 38. Kronenberg, M. 2005. Toward an understanding of NKT cell biology : progress and paradoxes. Annual Review of Immunology 23:877-900. 39. Akbari, O., P. Stock, E. Meyer, M. Kronenberg, S. Sidobre, T. Nakayama, M. Taniguchi, M. J. Grusby, R. H. DeKruyff, and D. T. Umetsu. 2003. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nature Medicine 9:582-588. 40. Umetsu, D. T., and R. H. DeKruyff. 2006. A role for natural killer T cells in asthma. Nature Reviews Immunology 6:953-958. 41. Zhou, D., J. Mattner, C. Cantu, III, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y.-P. Wu, T. Yamashita, S. Teneberg, D. Wang, R. L. Proia, S. B. Levery, P. B. Savage, L. Teyton, and A. Bendelac. 2004. Lysosomal glycosphingolipid recognition by NKT cells. Science 306:1786-1789. 42. Mattner, J., K. L. DeBord, N. Ismail, R. D. Goff, C. Cantu, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, K. Hoebe, O. Schneewind, D. Walker, B. Beutler, L. Teyton, P. B. Savage, and A. Bendelac. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434:525-529. 43. Kinjo, Y., E. Tupin, D. Wu, M. Fujio, R. Garcia-Navarro, M. R.-E.-I. Benhnia, D. M. Zajonc, G. Ben-Menachem, G. D. Ainge, G. F. Painter, A. Khurana, K. Hoebe, S. M. Behar, B. Beutler, I. A. Wilson, M. Tsuji, T. J. Sellati, C.-H. Wong, and M. Kronenberg. 2006. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nature Immunology 7:978-986. 44. Kinjo, Y., D. Wu, G. Kim, G.-W. Xing, M. A. Poles, D. D. Ho, M. Tsuji, K. Kawahara, C.-H. Wong, and M. Kronenberg. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434:520-525. 45. Fujii, S.-i., K. Shimizu, C. Smith, L. Bonifaz, and R. M. Steinman. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. Journal of Experimental Medicine 198:267-279. 46. Cerundolo, V., J. D. Silk, S. H. Masri, and M. Salio. 2009. Harnessing invariant NKT cells in vaccination strategies. Nature Reviews Immunology 9:28-38. 47. Yoshimoto, T., and W. Paul. 1994. CD4+, NK1.1+ T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. Journal of Experimental Medicine 179:1285-1295. 48. Kaer, L. V. 2005. α-galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nature Reviews Immunology 5:31-42. 49. Carnaud, C., D. Lee, O. Donnars, S.-H. Park, A. Beavis, Y. Koezuka, and A. Bendelac. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. Journal of Immunology 163:4647-4650. 50. Eberl, G., and H. R. MacDonald. 2000. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. European Journal of Immunology 30:985-992. 51. Fujii, S.-i., K. Liu, C. Smith, A. J. Bonito, and R. M. Steinman. 2004. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. Journal of Experimental Medicine 199:1607-1618. 52. Crowe, N. Y., A. P. Uldrich, K. Kyparissoudis, K. J. L. Hammond, Y. Hayakawa, S. Sidobre, R. Keating, M. Kronenberg, M. J. Smyth, and D. I. Godfrey. 2003. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. Journal of Immunology 171:4020-4027. 53. Taniguchi, M., K.-i. Seino, and T. Nakayama. 2003. The NKT cell system: bridging innate and acquired immunity. Nature immunology 4:1164-1165. 54. Kita, H., O. V. Naidenko, M. Kronenberg, A. A. Ansari, P. Rogers, X.-S. He, F. Koning, T. Mikayama, J. Van de Water, R. L. Coppel, M. Kaplan, and M. E. Gershwin. 2002. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123:1031-1043. 55. Chuang, Y.-H., Z.-X. Lian, G.-X. Yang, S.-A. Shu, Y. Moritoki, W. M. Ridgway, A. A. Ansari, M. Kronenberg, R. A. Flavell, B. Gao, and M. E. Gershwin. 2008. Natural killer T cells exacerbate liver injury in a transforming growth factor β-receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 47:571-580. 56. De Santo, C. 2008. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. Journal of Clinical Investigation 118:4036-4048. 57. Pham-Thi, N., J. de Blic, and M. C. Leite-De-Moraes. 2006. Invariant natural kIller T cells in bronchial asthma. The New England Journal of Medicine 354:2615-2615. 58. Sen, Y., B. Yongyi, H. Yuling, X. Luokun, H. Li, X. Jie, D. Tao, Z. Gang, L. Junyan, H. Chunsong, X. Zhang, J. Youxin, G. Feili, J. Boquan, and T. Jinquan. 2005. Vα24-invariant NKT cells from patients with allergic asthma express CCR9 at high frequency and induce Th2 bias of CD3+ T cells upon CD226 engagement. Journal of Immunology 175:4914-4926. 59. Pham-Thi, N., J. de Blic, M. Le Bourgeois, M. Dy, P. Scheinmann, and M. C. Leite-de-Moraes. 2006. Enhanced frequency of immunoregulatory invariant natural killer T cells in the airways of children with asthma. Journal of Allergy and Clinical Immunology 117:217-218. 60. Matangkasombut, P., G. Marigowda, A. Ervine, L. Idris, M. Pichavant, H. Y. Kim, T. Yasumi, S. B. Wilson, R. H. DeKruyff, J. L. Faul, E. Israel, O. Akbari, and D. T. Umetsu. 2009. Natural killer T cells in the lungs of patients with asthma. Journal of Allergy and Clinical Immunology 123:1181-1185.e1181. 61. Akbari, O., J. L. Faul, E. G. Hoyte, G. J. Berry, J. Wahlstrom, M. Kronenberg, R. H. DeKruyff, and D. T. Umetsu. 2006. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. The New England Journal of Medicine 354:1117-1129. 62. Lisbonne, M., S. Diem, A. de Castro Keller, J. Lefort, L. M. Araujo, P. Hachem, J.-M. Fourneau, S. Sidobre, M. Kronenberg, M. Taniguchi, P. Van Endert, M. Dy, P. Askenase, M. Russo, B. B. Vargaftig, A. Herbelin, and M. C. Leite-de-Moraes. 2003. Cutting edge: invariant Vα14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. Journal of Immunology 171:1637-1641. 63. Meyer, E. H., S. Goya, O. Akbari, G. J. Berry, P. B. Savage, M. Kronenberg, T. Nakayama, R. H. DeKruyff, and D. T. Umetsu. 2006. glycolipid activation of invariant T cell receptor+ NK T cells is sufficient to induce airway hyperreactivity independent of conventional CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America 103:2782-2787. 64. Matsuda, H., T. Suda, J. Sato, T. Nagata, Y. Koide, K. Chida, and H. Nakamura. 2005. α-galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. American Journal of Respiratory Cell and Molecular Biology 33:22-31. 65. Forestier, C., A. Molano, J. S. Im, Y. Dutronc, B. Diamond, A. Davidson, P. A. Illarionov, G. S. Besra, and S. A. Porcelli. 2005. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice. Journal of Immunology 175:763-770. 66. Fukushima, A., T. Sumi, K. Fukuda, T. Yamaguchi, N. Kumagai, T. Nishida, and H. Ueno. 2006. Modulation of murine experimental allergic conjunctivitis by treatment with α-galactosylceramide. Immunology Letters 107:32-40. 67. Rochman, Y., and W. J. Leonard. 2008. Thymic stromal lymphopoietin: a new cytokine in asthma. Current Opinion in Pharmacology 8:249-254. 68. Matsukura, S., C. Stellato, S. N. Georas, V. Casolaro, J. R. Plitt, K. Miura, S. Kurosawa, U. Schindler, and R. P. Schleimer. 2001. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. American Journal of Respiratory Cell and Molecular Biology 24:755-761. 69. Murphy, K. P. 2008. Janeway's immunobiology. Garland Science, New York. 70. Kim, J.-O., D.-H. Kim, W.-S. Chang, C. Hong, S.-H. Park, S. Kim, and C.-Y. Kang. 2004. Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model. Journal of Allergy and Clinical Immunology 114:1332-1338. 71. Parekh, V. V. 2005. Glycolipid antigen induces long-term natural killer T cell anergy in mice. Journal of Clinical Investigation 115:2572-2583. 72. Hachem, P., M. Lisbonne, M.-L. Michel, S. Diem, S. Roongapinun, J. Lefort, G. Marchal, A. Herbelin, P. W. Askenase, M. Dy, and M. C. Leite-de-Moraes. 2005. α-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-γ. European Journal of Immunology 35:2793-2802. 73. Courtney, A. N., P. N. Nehete, B. P. Nehete, P. Thapa, D. Zhou, and K. J. Sastry. 2009. α-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine 27:3335-3341. 74. Ko, S.-Y., H.-J. Ko, W.-S. Chang, S.-H. Park, M.-N. Kweon, and C.-Y. Kang. 2005. α-galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. Journal of Immunology 175:3309-3317. 75. Gombert, J.-M., A. Herbelin, E. Tancrède-Bohin, M. Dy, C. Carnaud, and J.-F. Bach. 1996. Early quantitative and functional deficiency of NK1+ -like thymocytes in the NOD mouse. European Journal of Immunology 26:2989-2998. 76. Mieza, M., T. Itoh, J. Cui, Y. Makino, T. Kawano, K. Tsuchida, T. Koike, T. Shirai, H. Yagita, A. Matsuzawa, H. Koseki, and M. Taniguchi. 1996. Selective reduction of Vα 14+ NK T cells associated with disease development in autoimmune-prone mice. Journal of Immunology 156:4035-4040. 77. Zhou, B., M. R. Comeau, T. D. Smedt, H. D. Liggitt, M. E. Dahl, D. B. Lewis, D. Gyarmati, T. Aye, D. J. Campbell, and S. F. Ziegler. 2005. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nature immunology 6:1047-1053. 78. Al-Shami, A., R. Spolski, J. Kelly, A. Keane-Myers, and W. J. Leonard. 2005. A role for TSLP in the development of inflammation in an asthma model. Journal of Experimental Medicine 202:829-839. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/9246 | - |
dc.description.abstract | 氣喘是一肺部發炎疾病,其臨床表徵為鳴喘、呼吸急促與呼吸道過度反應,許多免疫細胞都會參與發炎的過程,例如:T helper 2(Th2)cells和eosinophils。natural killer T cells(NKT cells)是一群特殊的T cells,它會表現natural killer cells和conventional T cells兩者的特性,目前在invariant natural killer cells(iNKT cells)的研究最多。當iNKT cells辨識由CD1d所呈獻的抗原如α-galactosylceramide(α-GalCer)而活化後,可在數小時內快速分泌多種且大量的細胞激素如interferon-γ(IFN-γ)和interleukin-4(IL-4),這獨特的特性使iNKT cell在許多疾病中扮演調控的角色。有關NKT cells在氣喘中扮演之角色先前研究的結果並不一致,有團隊證明NKT cells會促進氣喘的產生,但另有團隊卻證明NKT cells的活化會抑制呼吸道過度反應與呼吸道發炎反應。此外, NKT cells在某些疾病不同進程時扮演不同的角色。本研究的目的是探討是否NKT cells在氣喘不同疾病進程中亦扮演不同的角色,我們在氣喘疾病進程中不同時期以α-GalCer活化iNKT cells後測量小鼠呼吸道發炎之嚴重程度是否會不同以及其機轉。
我們利用ovalbumin(OVA)致敏引發氣喘的小鼠模式,在OVA致敏前或OVA致敏後給予α-GalCer,之後分析小鼠呼吸道發炎反應的程度。實驗結果顯示OVA致敏前給予α-GalCer的小鼠其呼吸道發炎反應高於致敏後才給予α-GalCer的小鼠,證實在氣喘疾病不同時期給予α-GalCer活化iNKT cells確實會使小鼠產生不同嚴重程度之呼吸道發炎反應。接著我們分析致敏前或致敏後給予α-GalCer兩小時與五天後小鼠的免疫反應之變化,發現在OVA致敏前給予α-GalCer可活化iNKT cells分泌大量的Th2 cytokines例如IL-4、IL-5與IL-13,及使肺部TSLP與eotaxin濃度升高,導致肺部浸潤細胞增多及IL-4的顯著上升。但若是在OVA致敏後才給予α-GalCer則造成Th2 cytokines與thymic stromal lymphopoietin (TSLP)的降低,終使小鼠呼吸道發炎反應不如OVA致敏前給予α-GalCer之小鼠嚴重。 這些結果顯示naïve環境下的iNKT cells與氣喘病Th2為主的環境下的iNKT cells其活化後產生的反應不同,最後造成呼吸道發炎反應之嚴重度不同。然而欲將α-GalCer當作呼吸道佐劑或治療性藥物的時候,需注意eosinophilia的可能性。 | zh_TW |
dc.description.abstract | Asthma is an inflammatory lung disease characterized by the expansion of T helper 2 (Th2) cells and eosinophils as well as the production of allergen-specific IgE. Natural killer T (NKT) cell is a unique subset of T cells that coexpresses T cell receptor (TCR) and natural killer (NK) cell markers. The most studied NKT cells are Type 1 NKT cells, which also referred to invariant natural killer T cell (iNKT cells). iNKT cells express semi-invariant CD1d-restricted αβ TCR, therefore they can recognize glycolipid antigens (like α-galactosylceramide (α-GalCer)) presented by CD1d molecules on antigen presenting cells. Once NKT cells are activated, they rapidly produce large amount of cytokines, such as interferon-γ (IFN-γ) and interleukin-4 (IL-4). Due to this unique characteristic, they have been implicated in the regulation of immune responses associated with a broad range of diseases.
In allergic asthma, the roles of iNKT cells are controversial. Some studies demonstrate that NKT cells are important in the development of asthma. However, others demonstrate that NKT cell activation before challenge abolishes the airway hyperresponsiveness and airway inflammation in experimental murine asthma models. These studies imply that NKT cells may play different roles in different asthma progression. Furthermore, this theory has been proved in some autoimmune diseases and allergic conjunctivitis. The aim of this study is to investigate the effect of activation of iNKT cells on the allergic airway inflammation and its mechanism. We administered BALB/c mice with α-GalCer, a stimulator for NKT cell activation, before or after ovalbumin (OVA) immunization and measured airway inflammation of those mice after 2 times of intranasal OVA challenge. In our results, the airway inflammation was more serious in mice that administered with α-GalCer before OVA immunization than that of after OVA immunization, suggesting that activation of iNKT cells in different asthma progression could lead to different severity of airway inflammation. Moreover, we analyzed the cell components and cytokines expression in lung after 2 hours and 5 days of α-GalCer administration to study the mechanism. Our data demonstrated that mice administered with α-GalCer before OVA immuniztion could activate iNKT cells to secrete large amount of Th2 cytokines, such as IL-4, IL-5 and IL-13, and increase eotaxin and thymic stromal lymphopoietin (TSLP) expression in bronchoalveolar lavage fluid (BALF), which recruit cell infiltrate in lung. In contrast, administration of α-GalCer after OVA immunization decreased Th2 cytokines, TSLP, and airway inflammation when compared to mice administered with a-GalCer before OVA immunization. Our data demonstrated that different immune response was noted in activation of naïve NKT cells and Th2-dominant environment NKT cells, which led to different outcome of airway inflammation in mice. However, the potential risks of treatment with NKT cell activation in human diseases should be considered. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T20:14:26Z (GMT). No. of bitstreams: 1 ntu-98-R96424023-1.pdf: 62515805 bytes, checksum: 4254e1ce1d1e452a2eebc4e81dc691fe (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 封面
口試委員審定書 授權書 致謝……………………………………………………………………………….. i 中文摘要………………………………………………………………………….. ii 英文摘要………………………………………………………………………….. iv 縮寫對照表……………………………………………………………………….. vi 目錄……………………………………………………………………………….. vii 圖目錄…………………………………………………………………………..… ix 第一章 研究背景………………………………………………………………… 1 1.1 氣喘之背景介紹……………………………...………………………… 1 1.1.1 發炎反應 (inflammatory response)……….………………….… 1 1.1.2 呼吸道過度反應 (airway hyperesponsiveness;AHR)….…….. 5 1.2 NKT cells之背景介紹…………………………………..……………… 6 1.2.1 NKT cells的定義…………………………..………………...… 6 1.2.2 iNKT cells的活化……………………………....……………… 6 1.2.3 NKT cells的生物功能…………………………..…………...… 7 1.3 NKT cells在氣喘中扮演的角色…………………………..…………… 8 1.4 NKT cells在疾病進程中,會扮演不同的角色..……………………… 9 1.5 研究目的………………………………………………………………… 10 第二章 實驗材料與方法……………….…………………………………...…… 11 2.1 實驗用小鼠……………………………………….………………...…… 11 2.2 氣喘動物模式之建立………………………….…………………...….... 11 2.3 α-GalCer 之給予…………………….….……………………...…...…… 11 2.4 血清樣品的收集…………….….…………………………………..……. 11 2.5 抽取小鼠支氣管肺泡沖洗液(bronchoalveolar lavage fluid;BALF )… 12 2.6 製備BAL cell玻片………….….…………………………………….… 12 2.7 流式細胞儀(flow cytometry)分析細胞表面抗原…………………….… 12 2.8 利用ELISA測量血清中OVA-specific IgE………………..………...… 13 2.9 利用ELISA測量BALF中細胞激素之濃度………………………...… 13 2.10 小鼠肺臟細胞初代培養……………………………………..………....... 14 2.11 以α-GalCer體外刺激肺臟初代細胞………………..………..............… 14 2.12 腹腔注射小鼠α-GalCer實驗………………..………..........................… 14 2.13 收集小鼠腹腔沖洗液………………..……….......................................… 15 2.14 繪圖及統計分析………………..……………………………………...… 15 第三章 結果………..……………………………………….…………………...… 16 3.1 小鼠在OVA致敏前與致敏後注射α-GalCer對於呼吸道發炎反 應嚴重程度之影響………………………….…………………….…...… 16 3.2 探討小鼠在OVA致敏前或致敏後給予α-GalCer兩小時後,肺 部的iNKT cells與細胞激素有何變化….……………………….…...… 17 3.3 以OVA致敏小鼠兩次後,其肺部的iNKT cells升高……….….....… 19 3.4 探討小鼠在OVA致敏前或致敏後給予α-GalCer五天後,肺部 之細胞組成與細胞激素有何變化.……………....……………….…...… 20 3.5 研究α-GalCer是否可直接影響初代培養之肺臟細胞產生eotaxin 之能力……………....…………………………………….……….…..… 22 3.6 探討腹腔注射α-GalCer是否吸引eosinophils至腹腔中…...….…....... 23 第四章 討論…………....…………………………………….………….….…..… 24 圖…………....…………………………………….……………………...….…..… 29 參考文獻…………………………………….……………………...….………..… 52 附錄…………………………………….……………………...….……………..… 61 | |
dc.language.iso | zh-TW | |
dc.title | 探討invariant NKT細胞的活化對於過敏性呼吸道發炎反應之影響 | zh_TW |
dc.title | The Effect of Activation of Invariant NKT Cells on the Allergic Airway Inflammation | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 江伯倫,繆希椿 | |
dc.subject.keyword | 氣喘,NKT細胞,呼吸道發炎反應,α-galactosylceramide (α-GalCer),支氣管肺泡沖洗液, | zh_TW |
dc.subject.keyword | asthma,natural killer T cell (NKT cell),airway inflammation,α-galactosylceramide (α-GalCer),bronchoalveolar lavage fluid (BALF), | en |
dc.relation.page | 64 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2009-07-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf | 61.05 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。